NASDAQ:RYTM

Rhythm Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy RYTM

*Your capital is at risk

$84.71

+0.360 (+0.427%)

At Close: Jun 03, 2026

Rhythm Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 34.39. In total, the insiders bought 890.31K and sold 98.16K RYTM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	34.39
● Buy	890.31K shares
● Sell	98.16K shares
67% Buy Activity Moderate Negative Correlation
Buy Signal Medium Confidence Feb 11, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 34.39. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 18, 2026 Buy	Stock Options (Right to Buy) M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	3 000 Value: $53.6K
May 18, 2026 Buy	Common Stock M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	3 000 Value: $53.6K
May 15, 2026 Buy	Stock Options (Right to Buy) M-Exempt	German Christopher Paul Corporate Controller & Cao	Officer	1 406 Value: $25.3K
May 15, 2026 Buy	Common Stock M-Exempt	German Christopher Paul Corporate Controller & Cao	Officer	1 687 Value: $95.6K
May 15, 2026 Sell	Common Stock S-Sale	German Christopher Paul Corporate Controller & Cao	Officer	4 643 Value: $428.1K
May 15, 2026 Buy	Stock Options (Right to Buy) M-Exempt	German Christopher Paul Corporate Controller & Cao	Officer	1 687 Value: $95.6K
May 15, 2026 Buy	Common Stock M-Exempt	German Christopher Paul Corporate Controller & Cao	Officer	1 349 Value: $66.4K
May 15, 2026 Buy	Stock Options (Right to Buy) M-Exempt	German Christopher Paul Corporate Controller & Cao	Officer	1 349 Value: $66.4K
May 15, 2026 Buy	Common Stock M-Exempt	German Christopher Paul Corporate Controller & Cao	Officer	1 406 Value: $25.3K
Apr 01, 2026 Buy	Common Stock M-Exempt	Mazabraud Yann EVP, Head Of International	Officer	12 875 Value: $1.13M
Apr 01, 2026 Buy	Restricted Stock Units M-Exempt	Mazabraud Yann EVP, Head Of International	Officer	10 375 Value: $914.2K
Apr 01, 2026 Buy	Restricted Stock Units M-Exempt	Mazabraud Yann EVP, Head Of International	Officer	2 500 Value: $220.3K
Apr 01, 2026 Buy	Stock Options (Right to Buy) A-Award	Popovits Kimberly J Director	Director	10 257 Value: $903.8K
Apr 01, 2026 Buy	Restricted Stock Units A-Award	Popovits Kimberly J Director	Director	6 808 Value: $599.9K
Apr 01, 2026 Buy	Common Stock J-Other	Popovits Kimberly J	Director	0 Value: $0
Mar 12, 2026 Buy	Common Stock J-Other	Mathers Edward T Director	Director	4 199 Value: $382.7K
Mar 04, 2026 Sell	Common Stock S-Sale	German Christopher Paul Corporate Controller & Cao	Officer	5 614 Value: $502.8K
Mar 04, 2026 Buy	Stock Options (Right to Buy) M-Exempt	German Christopher Paul Corporate Controller & Cao	Officer	1 500 Value: $27.0K
Mar 04, 2026 Buy	Common Stock M-Exempt	German Christopher Paul Corporate Controller & Cao	Officer	1 500 Value: $27.0K
Mar 02, 2026 Buy	Common Stock J-Other	Mathers Edward T Director	Director	4 198 Value: $398.6K
Mar 02, 2026 Buy	Stock Options (Right to Buy) A-Award	Mazabraud Yann EVP, Head Of International	Officer	35 000 Value: $3.32M
Mar 02, 2026 Buy	Stock Options (Right to Buy) M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	6 099 Value: $41.5K
Mar 02, 2026 Buy	Common Stock M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	6 099 Value: $41.5K
Mar 01, 2026 Buy	Restricted Stock Units M-Exempt	German Christopher Paul Corporate Controller & Cao	Officer	1 162 Value: $98.4K
Mar 01, 2026 Sell	Common Stock F-InKind	German Christopher Paul Corporate Controller & Cao	Officer	342 Value: $32.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RHYTHM PHARMACEUTICALS INC

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström s...

Read Full Profile Here